EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity

Ricardo J Samms, Kyle W Sloop iD

Diabetes · 01.08.2025 · 74 (8) · 1326-1333

DOI: 10.2337/dbi24-0026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 16.06.2025. Verfasst von Ricardo J Samms und 1 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Obesity. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In combatting the obesity crisis, leveraging mechanisms that lower body weight is critical. The finding that treatment with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, produces profound weight loss highlights the value of activating the incretin receptors. Supporting this, recent studies have revealed mechanisms by which GIP receptor (GIPR) activation is beneficial in pancreatic islets, the central nervous system (CNS), and adipose tissue. Paradoxically, a hypothesis has emerged that GIPR antagonism could be an additional option in treating obesity. This concept stems from concern that GIP facilitates lipid uptake and storage in adipose tissue, although the lipid-buffering capacity of adipocytes versus other cell types is metabolically favorable. In this article, we highlight the natural physiology of the incretins, noting GIP as the primary incretin. In the CNS, GIPR agonism attenuates nausea and suppresses appetite, features that also help GLP-1 receptor agonism promote a negative energy balance. Further, we provide rationale that, in protecting against ectopic fat distribution and augmenting substrate utilization to promote insulin sensitivity, GIPR activity in adipose tissue is advantageous. Collectively, these attributes support GIPR agonism in the treatment of obesity and metabolic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Gastrointestinal HormoneObesityHumansAnimalsGastric Inhibitory PolypeptideIncretinsGlucagon-Like Peptide-1 Receptor AgonistsAdipose Tissue

Substanzen

Receptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGastric Inhibitory PolypeptideIncretinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.

ORCID-Profile: Kyle W Sloop

Zitieren

APA

Samms, R. J., & Sloop, K. W. (2025). A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes, 74(8), 1326-1333. https://doi.org/10.2337/dbi24-0026

Vancouver

Samms RJ, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025;74(8):1326-1333. doi:10.2337/dbi24-0026

BibTeX
@article{Samms2025,
  author = {Samms, Ricardo J and Sloop, Kyle W},
  title = {A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {8},
  pages = {1326--1333},
  doi = {10.2337/dbi24-0026}
}
Kostenlos starten →